+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cluster Headache Market - Global Forecast 2026-2032- Product Image
Cluster Headache Market - Global Forecast 2026-2032- Product Image
New

Cluster Headache Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 187 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5968098
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cluster Headache Market is undergoing rapid transformation, with innovation across therapeutic and operational fronts redefining approaches for industry stakeholders. Evolving patient care and regulatory landscapes are increasing complexity, emphasizing the need for strategic collaboration and resilience.

Market Snapshot: Cluster Headache Market Growth and Opportunities

The global cluster headache market is experiencing notable expansion, growing from USD 425.19 million in 2025 to USD 451.77 million in 2026 and forecasted to reach USD 636.61 million by 2032, with a CAGR of 5.93%. This momentum is propelled by increased recognition of cluster headache as a severe neurological emergency, continued adoption of biologic therapies, and rising demand for advanced device-based treatments. Industry focus is intensifying as diversification of care delivery, evolving supply chain strategies, and commercialization of new therapeutic options create fresh opportunities for differentiation in healthcare markets worldwide.

Scope & Segmentation: Structured Insights Across Clinical Pathways and Commercial Channels

  • Treatment Types: Nonpharmaceutical interventions include behavioral therapy, neuromodulation, and oxygen therapy. Pharmaceutical options encompass anti-CGRP monoclonal antibodies, NSAIDs, and triptans, reflecting a comprehensive range of care modalities.
  • Drug Classes: The market comprises anti-CGRP monoclonal antibodies, NSAIDs, oxygen therapy, and triptans, each with unique clinical attributes and applicability across patient sub-populations.
  • Administration Routes: Inhalation, nasal, oral, and subcutaneous delivery offer varying onset times, adherence profiles, and accessibility according to patient and provider needs.
  • End-User Settings: Care is delivered across home environments, hospital emergency and neurology departments, specialty clinics, headache centers, and dedicated neurology clinics, reflecting a diversified service landscape.
  • Distribution Channels: Hospital pharmacies, online platforms, retail outlets, and specialty pharmacies shape patient access, influence experience, and impact formulary positioning.
  • Payer Types: Government reimbursement, private insurance, and direct out-of-pocket spending each define market access, affordability, and long-term adoption trends.
  • Geography: Americas, Europe, Middle East & Africa, and Asia-Pacific provide regional perspectives on care models, payer dynamics, and local technology adoption, revealing differences in regulatory environments and healthcare delivery models.

Technology and Regional Dynamics

Advances in biopharmaceuticals, particularly anti-CGRP biologics, are complemented by neuromodulation device development and increased adoption of telemedicine to extend clinical expertise and enable remote monitoring. North America features integrated specialty and primary care, Europe prioritizes evidence-based access pathways, and the Asia-Pacific region leverages local manufacturing capabilities to scale access. These differences necessitate nuanced market entry and scaling strategies for stakeholders aiming to optimize regional growth and innovation adoption.

Key Takeaways for Strategic Decision-Makers

  • Integrated multimodal care is enhancing clinical outcomes, with combined use of pharmaceuticals, devices, oxygen therapies, and behavioral approaches gaining broader acceptance among care teams.
  • Commercial strategies must align with fragmented patient journeys, accounting for distinct levels of patient and provider awareness, and adapting engagement models accordingly.
  • Digital health tools, especially telemedicine and remote monitoring platforms, are supporting continuity of care and augmenting specialty access beyond traditional acute-care settings.
  • Payers and regulators are demanding robust comparative evidence on both clinical effectiveness and cost efficiency to inform market access and utilization, influencing adoption rates and reimbursement decisions.
  • Supply chain planning increasingly requires diversified sourcing and proactive risk management as industry responds to new operational pressures, including trade-related disruptions.
  • Cross-industry partnerships between pharmaceutical firms, medtech players, and distributors are fostering bundled offerings, bolstering value proposition communications, and facilitating more effective delivery to end users.

Tariff Impact: Strategic Supply Chain Adjustments

Recent tariff adjustments have introduced new cost pressures and procurement challenges for suppliers of therapeutics and medical devices. Industry leaders are countering these disruptions through supply chain diversification, prioritization of nearshoring arrangements, and reassessment of purchasing contracts with key distribution stakeholders. Hospitals and specialty pharmacies are increasing focus on contract stability and predictable supply to mitigate risks, while insurance payers seek clear, data-driven justifications for coverage of novel approaches. Maintaining robust collaboration among manufacturers, distributors, and health systems is critical to assure ongoing patient access despite external volatility.

Methodology & Data Sources

This report synthesizes insights from primary interviews with clinicians, supply chain executives, and industry specialists, combined with secondary analysis of peer-reviewed publications, official guidelines, and validated market datasets. Rigorous triangulation and cross-disciplinary review confirm actionable, real-world relevance for decision-makers.

Why This Report Matters

  • Offers clear visibility into the intersection of clinical innovation, evolving regulation, and payer strategies affecting the cluster headache market landscape.
  • Guides manufacturers, providers, and payers with actionable recommendations for strengthening supply chains, enhancing patient support programs, and achieving commercial success.
  • Supports strategic planning with transparent, validated insights drawn from multiple robust data sources and mapped to real-world business and clinical contexts.

Conclusion

The Cluster Headache Market is evolving as new therapeutics, technology integration, and adaptive care models reshape strategies. Stakeholders that emphasize patient outcomes and resilient operations will position themselves successfully in the changing environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cluster Headache Market, by Treatment Type
8.1. Nonpharmaceutical
8.1.1. Behavioral Therapy
8.1.2. Neuromodulation
8.1.3. Oxygen Therapy
8.1.3.1. Delivery Systems
8.1.3.1.1. Portable
8.1.3.1.2. Stationary
8.1.3.2. Inhalation
8.2. Pharmaceutical
8.2.1. Anti-CGRP Monoclonal Antibodies
8.2.1.1. Erenumab
8.2.1.2. Fremanezumab
8.2.1.3. Galcanezumab
8.2.2. NSAIDs
8.2.3. Triptans
8.2.3.1. Rizatriptan
8.2.3.2. Sumatriptan
8.2.3.3. Zolmitriptan
9. Cluster Headache Market, by Drug Class
9.1. Anti-CGRP Monoclonal Antibodies
9.1.1. Erenumab
9.1.2. Fremanezumab
9.1.3. Galcanezumab
9.2. NSAIDs
9.3. Oxygen Therapy
9.3.1. Delivery Systems
9.3.1.1. Portable
9.3.1.2. Stationary
9.3.2. Inhalation
9.4. Triptans
9.4.1. Rizatriptan
9.4.2. Sumatriptan
9.4.3. Zolmitriptan
10. Cluster Headache Market, by Route Of Administration
10.1. Inhalation
10.2. Nasal
10.3. Oral
10.4. Subcutaneous
11. Cluster Headache Market, by Payer Type
11.1. Government Reimbursement
11.2. Out-Of-Pocket
11.3. Private Insurance
12. Cluster Headache Market, by End User
12.1. Home Care
12.2. Hospital
12.2.1. Emergency Department
12.2.2. Neurology Department
12.3. Specialty Clinics
12.3.1. Headache Centers
12.3.2. Neurology Clinics
13. Cluster Headache Market, by Distribution Channel
13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies
13.4. Specialty Pharmacies
14. Cluster Headache Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Cluster Headache Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Cluster Headache Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Cluster Headache Market
18. China Cluster Headache Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Amgen Inc.
19.7. AstraZeneca plc
19.8. Biogen, Inc.
19.9. Boehringer Ingelheim International GmbH
19.10. electroCore, Inc.
19.11. Eli Lilly and Company
19.12. GlaxoSmithKline PLC
19.13. Lundbeck LLC
19.14. Lupin Limited
19.15. Pfizer Inc.
19.16. Sun Pharmaceutical Industries Ltd.
19.17. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES CLUSTER HEADACHE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA CLUSTER HEADACHE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OUT-OF-POCKET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OUT-OF-POCKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PRIVATE INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PRIVATE INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HEADACHE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HEADACHE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HEADACHE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 171. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 172. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 173. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 174. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 175. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 176. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 177. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 178. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 179. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 180. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 181. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 182. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 183. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 184. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 186. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 188. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 189. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 191. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 192. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 194. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 198. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 201. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 202. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 203. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 205. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 212. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 214. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 215. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 216. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 217. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 219. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 220. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 221. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 222. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 224. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 226. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. EUROPE CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. EUROPE CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 249. EUROPE CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 250. EUROPE CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 251. EUROPE CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 252. EUROPE CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 253. EUROPE CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 254. EUROPE CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 255. EUROPE CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 256. EUROPE CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 257. EUROPE CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 258. EUROPE CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 259. EUROPE CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 260. EUROPE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. EUROPE CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 262. EUROPE CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 263. EUROPE CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 264. EUROPE CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 265. EUROPE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 267. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 268. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 269. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 270. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 271. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 272. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 273. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 274. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 275. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 276. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 277. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 278. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 279. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 280. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 281. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 282. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 283. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 284. MIDDLE EAST CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 285. AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 286. AFRICA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 287. AFRICA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 288. AFRICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 289. AFRICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 290. AFRICA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 291. AFRICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 292. AFRICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 293. AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 294. AFRICA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 295. AFRICA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 296. AFRICA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 297. AFRICA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 298. AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 299. AFRICA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 300. AFRICA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 301. AFRICA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 302. AFRICA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 303. AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 305. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 306. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 307. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 308. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 309. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 310. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 311. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 312. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 313. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 314. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 315. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 316. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 317. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 318. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 319. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 320. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 321. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 322. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 323. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 324. ASEAN CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 325. ASEAN CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 326. ASEAN CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 327. ASEAN CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2032 (USD MILLION)
TABLE 328. ASEAN CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
TABLE 329. ASEAN CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 330. ASEAN CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 331. ASEAN CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 332. ASEAN CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 333. ASEAN CLUSTER HEA

Companies Mentioned

The key companies profiled in this Cluster Headache market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • electroCore, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Lundbeck LLC
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages187
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 451.77 Million
Forecasted Market Value ( USD ) by 2032 $ 636.61 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Cluster Headache Market - Global Strategic Business Report - Product Image

Cluster Headache Market - Global Strategic Business Report

  • Report
  • 471 Pages
  • Global
From
Cluster Headache Syndrome- Pipeline Insight, 2025 - Product Image

Cluster Headache Syndrome- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Cluster Headache - Pipeline Insight, 2025 - Product Image

Cluster Headache - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Clonixin Market - Global Forecast 2026-2032 - Product Image

Clonixin Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Cluster Headache Syndrome Drug Market

Cluster Headache Syndrome (CHS) is a rare neurological disorder characterized by severe, debilitating headaches. It is estimated to affect approximately 0.1% of the population. Treatment for CHS is typically divided into two categories: acute and preventive. Acute treatments are used to provide immediate relief from the pain of a cluster headache attack, while preventive treatments are used to reduce the frequency and severity of attacks. The Cluster Headache Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of pharmaceuticals used to treat CHS, including triptans, ergot alkaloids, and corticosteroids. These drugs are typically administered orally, intranasally, or subcutaneously. The Cluster Headache Syndrome Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.